Evidence map›Paper›PMID 39901520›Full record

ArticleClinical pharmacology in drug development2025

Bioavailability, Metabolism, and Excretion of [

Yingxue Chen, Renli Teng, Julien Ogier

Registry-linked trialAbstract readMulticenter StudyClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology in drug development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03010982 (An Open-Label, Multi-Center, Two-Part, Phase 1 Study to Characterize the Pharmacokinetics of an Intravenous Micro-Dose of [14C]-Tazemetostat), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03010982 phase1completednot on this map

An Open-Label, Multi-Center, Two-Part, Phase 1 Study to Characterize the Pharmacokinetics of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the Absorption, Distribution, Metabolism and Elimination of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Advanced Solid Tumors

TypeinterventionalSponsorEpizyme, Inc.Ran2018 to 2019Enrolled3ConditionsDiffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle-Cell Lymphoma, Follicular LymphomaArmsTazemetostat and [14C] Tazemetostat
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yingxue ChenClinical Pharmacology, DMPK and Pharmacometrics, Ipsen Bioscience Inc., Cambridge, MA, USA.
Renli TengCareCeutics, LLC, Berwyn, PA, USA.
Julien OgierClinical Pharmacology, DMPK and Pharmacometrics, Ipsen Innovation, Les Ulis, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This open-label, multicenter study (NCT03010982) evaluated the absolute bioavailability, characterized the disposition and metabolism, and investigated the metabolic profile of tazemetostat, a US Food and Drug Administration-approved inhibitor of enhancer of zeste homolog 2, following intravenous and oral [

Indexed as

Antineoplastic AgentsBiphenyl CompoundsLymphoma, B-CellMorpholinesNeoplasmsAdministration, OralAdultAgedAged, 80 and overBenzamidesBiological AvailabilityCarbon RadioisotopesFemaleHumansMaleMiddle AgedAntineoplastic AgentsBenzamidesBiphenyl CompoundsCarbon RadioisotopesMorpholinesPyridonestazemetostatbioavailabilitydrug excretiondrug metabolismpharmacokineticstazemetostat

Identifiers

PMID39901520
PMCPMC11905873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.